Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 16 Issue 3, September 2022

In this issue...

• Oncology’s highest-value deals: top ten

• Mergers and acquisitions in CNS diseases

• Big pharma dominates antibody dealmaking

• Biopharma dealmaking in 2022 so far

Superresolution image of a cluster of killer T cells (green and red) enveloping a cancer cell (blue, center). BSIP SA / Alamy Stock Photo.

High-value dealmaking strengthens big pharma’s CNS ambitions

Top of page ⤴

Top ten oncology partnerships

  • Feature

    • Since 2021, the oncology sector has seen a string of billion-dollar deals.

      • Biopharma Dealmakers
      • DealForma, LLC
      News Feature
  • Profiles

    • IO Biotech is developing T-win, a therapeutic cancer-vaccine technology designed to recruit naturally occurring T cells to disrupt multiple immunosuppressive processes in the tumor microenvironment. The lead candidate is in advanced clinical development for melanoma with plans to expand to other solid tumor indications.

      • IO Biotech, Inc
      Advertisement Feature
    • A next-generation diagnostic test developed by Haystack Oncology detects the presence of micrometastatic disease in patients who have received surgery for early-stage cancer. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA—physicians can help their patients receive the appropriate type and duration of treatment and in doing so improve patient outcomes.

      • Haystack Oncology
      Advertisement Feature
    • OncXerna Therapeutics is pioneering the use of artificial intelligence (AI) in the development of drugs and biomarkers for cancer, targeting patients’ tumor microenvironment (TME) to develop a precision-medicine approach that might identify those who will benefit most from the treatments in its pipeline.

      • OncXerna Therapeutics
      Advertisement Feature
    • Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

      • Synaffix
      Advertisement Feature
    • Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.

      • MetasTx
      Advertisement Feature
    • With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

      • Janssen Oncology
      Advertisement Feature
    • A novel platform that incorporates the human extracellular matrix is helping to accelerate drug development for diseases including fibrosis and solid tumors.

      • Engitix Therapeutics
      Advertisement Feature
    • Precision diagnostics and monitoring company Oncocyte is developing the most comprehensive and rapid tumor-microenvironment gene-expression test to assess immunotherapeutic responsiveness. Combined with the company’s other tests, it provides a complete solution for cancer immunotherapy management and monitoring.

      • Oncocyte Corporation
      Advertisement Feature
    • Nabla Bio combines innovative artificial intelligence with proprietary wet-lab biology to design, refine and optimize next-generation therapeutic antibodies.

      • Nabla Bio
      Advertisement Feature
    • HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.

      • HOOKIPA Pharma Inc.
      Advertisement Feature
Top of page ⤴

Antibody dealmaking driven by oncology

  • Feature

    • Recent major antibody deals involve immune checkpoint inhibitors, antibody–drug conjugates and natural killer cell engagers for cancer.

      • Biopharma Dealmakers
      • DealForma, LLC
      News Feature
  • Profiles

    • Marengo Therapeutics’ breakthrough discovery in T cell receptor (TCR) activation blazes a new trail for safe treatment and long-term protection against cancer.

      • Marengo Therapeutics
      Advertisement Feature
    • From antigen design to cell-line development for the successful production of biologics.

      • Fusion Antibodies
      Advertisement Feature
    • California-based Alamar Biosciences is beating antibodies at their own game, boosting affinity by targeting multiple epitopes on the same antigen using its Attobody platform.

      • Alamar Biosciences, Inc.
      Advertisement Feature
Top of page ⤴

Big bets on new cancer therapies and how to find them

Top of page ⤴

Search

Quick links